TNFRSF12A anticorps (PE)
-
- Antigène Voir toutes TNFRSF12A Anticorps
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
-
Reactivité
- Humain, Souris
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp TNFRSF12A est conjugé à/à la PE
-
Application
- Flow Cytometry (FACS)
- Specificité
- The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
- Réactivité croisée (Details)
- Human, Mouse
- Purification
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogène
- human CD266-transfected P815 cells
- Clone
- ITEM-4
- Isotype
- IgG2b
- Top Product
- Discover our top product TNFRSF12A Anticorps primaire
-
-
- Indications d'application
- Flow cytometry: Recommended dilution: 2-4 μg/mL.
- Commentaires
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
- Restrictions
- For Research Use only
-
- Concentration
- 0.1 mg/mL
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C
- Stockage commentaire
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." dans: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
: "Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 185, Issue 3, pp. 1593-605, (2010) (PubMed).
: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).
: "
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." dans: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
-
- Antigène
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
- Autre désignation
- CD266 / TWEAK R (TNFRSF12A Produits)
- Synonymes
- anticorps CD266, anticorps FN14, anticorps TWEAKR, anticorps AI255180, anticorps C87282, anticorps Fn14, anticorps HPIP, anticorps TWEAK-R, anticorps TweakR, anticorps TNF receptor superfamily member 12A, anticorps tumor necrosis factor receptor superfamily, member 12a, anticorps TNFRSF12A, anticorps Tnfrsf12a
- Sujet
- TNF receptor superfamily member 12A,CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.,TWEAKR, FN14, TNFRSF12A
- ID gène
- 51330
- UniProt
- Q9NP84
- Pathways
- Apoptose, Regulation of Cell Size
-